As we approach another unpredictable respiratory season, the critical role of swift and accurate diagnosis of respiratory diseases in optimizing patient outcomes, minimizing unnecessary antimicrobial usage, and conserving health system resources cannot be overstated. This crucial function has become even more prominent given the post-pandemic decentralization of healthcare delivery, calling for a dynamic and strategic approach to diagnostic testing.
A 2018 study highlighted upper respiratory infections as the primary cause of treat-and-release visits in emergency departments due to their prevalence. However, as our healthcare landscape continues to change in the wake of COVID-19, much of this outpatient workload has transitioned to urgent care centers, retail clinics, and outpatient testing centers, indicating a significant shift in healthcare delivery models. This change has seen the use of urgent care centers spike substantially, with patient visits per center growing by 60% from 2019 to 2020, and managing 206 million non-emergent visits in 2022 alone. Parallel to the increased reliance on these centers, the number of freestanding urgent care centers has risen from 7,220 in 2014 to an impressive 14,382 in 2023.
This shift has made urgent care a cornerstone of accessible and convenient healthcare delivery, particularly for infectious diseases with overlapping symptomatology. Respiratory conditions in 2023 accounted for almost a quarter of all ICD-10 codes used in urgent care, attesting to the vital role of these centers in delivering expedient diagnoses and treatment. As the use of these centers continues to grow, it is paramount to equip them with on-site solutions that enhance timely diagnosis. Doing so improves treatment guidance prevents inappropriate treatment, and minimizes unnecessary emergency department visits.
Last year’s respiratory season proved taxing for the nation. The clinical complexity was heightened by the re-emergence of Mycoplasma pneumoniae infections and the rising incidence of whooping cough. Additionally, the CDC and other health agencies initiated enhanced monitoring of novel influenza A infections following H5N1 avian flu outbreaks in poultry and associated human infections. This increased observational stance underscores how seasonal unpredictability, the resurgence of bacterial pathogens, and the threat of new virus strains can converge to create a backdrop for postponed diagnoses.
Delayed diagnoses not only jeopardize patient outcomes but can also place substantial strain on healthcare systems. With the ongoing trend of healthcare decentralization, strategic deployment of diagnostic resources and testing becomes integral to provide a suitable, comprehensive response to the unpredictable emergence of common and new pathogens. The introduction of molecular point-of-care testing (mPOCT) in decentralized care settings affords lab-quality polymerase chain reaction (PCR) testing closer to the patient, and with turnaround times as fast as 15 minutes.
PCR testing provides reliable early detection in disease progression, thus giving healthcare professionals crucial, actionable results to guide patient treatment. The ability of syndromic testing to detect multiple pathogens from a single sample proves instrumental in differentiating co-circulating pathogens with similar symptom profiles during peak season. Implementing molecular testing in decentralized settings could be a strategic key to delivering better, more cost-effective care, promoting antimicrobial stewardship initiatives, reducing avoidable emergency department visits, and aligning healthcare with value-based care priorities.
The strategic implementation of diagnostic resources, including mPOCT, necessitates a series of conscious decisions and action steps to improve patient-center diagnostic testing. Undertaking assessments to identify current diagnostic inefficiencies across different touchpoints is fundamental. Gathering insights from clinicians could reveal unmet needs and noticeable opportunities to augment diagnostic capabilities. Investing in infrastructures that cater to real-time testing needs and anticipating evolving patient needs are vital steps towards efficient diagnostic testing. Working in tandem with operations and quality managers could streamline the integration of new technologies into existing workflows.
Furthermore, seek to align with payers to optimize reimbursement strategies for diagnostic testing. Diagnostic stewardship becomes incredibly important, necessitating the establishment of comprehensive governance around test usage. Collaborative efforts with team leads to design specific training modules for healthcare staff could facilitate a smoother integration of mPOCT into current workflows. Addressing any resistance to new workflows and identifying clinical champions are invaluable steps in refining and improving workflows.
Lastly, tracking key performance indicators from the inception of diagnostic testing could evaluate operational and economic impacts effectively in the long run. In conclusion, the ever-evolving healthcare landscape calls for strategically deployed diagnostics to follow the shift of care towards the patient. An investment in molecular testing in decentralized settings paves the path to delivering more efficient, timely, and cost-effective care, ensuring that minor illnesses do not translate into major burdens on the healthcare system.